March 4, 2025
At MGH we reached a milestone on March 4, 2025: one year of being able to administer lecanemab, the first new amyloid-lowering therapy for patients with early-stage Alzheimer’s disease. Working closely with our colleagues at the Brigham, we have implemented a high quality process for determining which patients are eligible for safe administration of this new treatment. Collectively, we have treated more than 250 people with early-stage AD. “I am honored to reflect on this past year, which started with all of the uncertainties that are naturally present whenever we start using a new treatment. We have not had any major safety issues and the process has been largely very smooth with amazing teamwork across AD specialists, radiologists, and infusion clinicians.” – Brad Dickerson, MD